T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.62B |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$1.61B |
| 3 |
Amazon
AMZN
|
+$1.18B |
| 4 |
Lam Research
LRCX
|
+$1.17B |
| 5 |
Las Vegas Sands
LVS
|
+$1.01B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Yum! Brands
YUM
|
+$1.4B |
| 2 |
Apple
AAPL
|
+$1.26B |
| 3 |
Tesla
TSLA
|
+$1.13B |
| 4 |
JPMorgan Chase
JPM
|
+$1.11B |
| 5 |
Morgan Stanley
MS
|
+$1.1B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.93% |
| 2 | Healthcare | 16.29% |
| 3 | Consumer Discretionary | 15.16% |
| 4 | Financials | 15.14% |
| 5 | Communication Services | 9.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNTA
1251
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $16.8M | ﹤0.01% |
819,190
+10,192
| +1% | +$219K |
|
1252
Pinnacle West Capital
PNW
$12.2B
| $16.6M | ﹤0.01% |
206,038
-6,888
| -3% | -$539K |
|
1253
Globe Life
GL
$14B
| $16.6M | ﹤0.01% |
203,580
+461
| +0.2% | +$39.1K |
|
1254
International Flavors & Fragrances
IFF
$21.4B
| $16.6M | ﹤0.01% |
133,624
-540
| -0.4% | -$70.6K |
|
1255
iShares MSCI India ETF
INDA
$6.58B
| $16.6M | ﹤0.01% |
497,459
+162,459
| +48% | +$5.51M |
|
1256
UDR
UDR
$12.2B
| $16.5M | ﹤0.01% |
439,387
| – | – |
|
1257
LKQ Corp
LKQ
$6.38B
| $16.5M | ﹤0.01% |
516,981
+36
| +0% | +$1.2K |
|
1258
Empire State Realty Trust
ESRT
$836M
| $16.4M | ﹤0.01% |
961,560
-14,344
| -1% | -$242K |
|
1259
Avery Dennison
AVY
$13.6B
| $16.4M | ﹤0.01% |
160,847
+2,319
| +1% | +$245K |
|
1260
Magnolia Oil & Gas
MGY
$6.13B
| $16.4M | ﹤0.01% |
+1,509,909
| New | +$15.7M |
|
|
FPRX
1261
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $16.4M | ﹤0.01% |
1,037,941
-96,124
| -8% | -$1.68M |
|
1262
Leidos
LDOS
$17.9B
| $16.3M | ﹤0.01% |
276,322
+16,114
| +6% | +$1M |
|
1263
Diageo
DEO
$52.8B
| $16.3M | ﹤0.01% |
113,123
-6,298
| -5% | -$902K |
|
1264
NETSCOUT
NTCT
$2.89B
| $16.2M | ﹤0.01% |
546,489
+5,981
| +1% | +$166K |
|
|
ECHO
1265
EchoStar
ECHO
$26.6B
| $16.2M | ﹤0.01% |
449,482
-3,058
| -0.7% | -$125K |
|
1266
Stepan Co
SCL
$1.48B
| $16M | ﹤0.01% |
205,024
+2,114
| +1% | +$161K |
|
|
SFE
1267
DELISTED
Safeguard Scientifics, Inc.
SFE
| $15.8M | ﹤0.01% |
1,235,121
-132,827
| -10% | -$1.71M |
|
1268
Paycom
PAYC
$10.1B
| $15.6M | ﹤0.01% |
157,881
-2
| -0% | -$216 |
|
|
MYOV
1269
DELISTED
Myovant Sciences Ltd.
MYOV
| $15.4M | ﹤0.01% |
674,703
+196,094
| +41% | +$4.28M |
|
1270
Sabre
SABR
$892M
| $15.4M | ﹤0.01% |
625,205
-1,546,995
| -71% | -$35.9M |
|
1271
Western Union
WU
$2.34B
| $15.3M | ﹤0.01% |
754,053
+111
| +0% | +$2.21K |
|
1272
Everest Group
EG
$14B
| $15.1M | ﹤0.01% |
65,486
-7,297
| -10% | -$1.71M |
|
1273
AES
AES
$10.5B
| $15M | ﹤0.01% |
1,121,096
| – | – |
|
|
DISCK
1274
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $14.9M | ﹤0.01% |
586,039
+48,540
| +9% | +$1.08M |
|
|
ITCI
1275
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $14.9M | ﹤0.01% |
841,188
-302,452
| -26% | -$6.14M |
|
Similar funds
T. Rowe Price Associates's Q2 2018 Portfolio in Review
As of Q2 2018, T. Rowe Price Associates held 2,648 positions worth $654B, up 4% from $629B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2018 filing shows 98 new, 1,625 increased, 741 reduced and 68 closed positions. Its largest new stake was Evergy: 16,595,898 shares worth $932M. The largest sale was Yum! Brands, an estimated $1.4B.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2018 buy was Evergy: 16,595,898 shares worth $932M.
- T. Rowe Price Associates added most to Meta Platforms (Facebook) in Q2 2018, an estimated $1.62B increase.
- T. Rowe Price Associates's biggest Q2 2018 reduction was Yum! Brands, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited CSRA Inc. in Q2 2018, selling an estimated $912M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $654B portfolio in Q2 2018.
- T. Rowe Price Associates opened 98 new positions and closed 68 in Q2 2018.
- T. Rowe Price Associates's portfolio value rose 4% quarter-over-quarter to $654B.
Based on T. Rowe Price Associates's 13F filing for Q2 2018, filed 14 Aug 2018.